Alias:  KEOXIFENE; AKOS 9213 Purity: 99% MF: C28H28ClNO4S MW: 510.04 Appearance: Light yellow powder Related Substances: Pharmaceutical Grade Storage: Shading, confined preservation Manufacturer: YuanCheng Lead time: 1-2 days upon receipt of payment Usage: It is used in the prevention of osteoporosis in postmenopausal women. |
Description
KEOXIFENE is a second-generation Selective Estrogen Receptor Modulator (SERM) of the benzothiophene family. This drug is similar in effect to , exhibiting estrogen receptor antagonist (blocking) properties in some tissues while acting as an estrogen receptor agonist (activator) in others.
The main point of variation between these two agents is their tissue selectivity. While KEOXIFENE is a strong anti-estrogen in breast and uterine tissues, it appears to be estrogenic in bone. This allows it to protect bone density, mimicking the beneficial effects of endogenous estradiol. This is quite different from KEOXIFENE, which is anti-estrogenic in both breast and bone.
In a role that was novel for an anti-estrogen,KEOXIFENE was approved by the FDA for the prevention and treatment of osteoporosis in post-menopausal women. It is also being investigated for several other potential uses, including the treatment and prevention of cardiovascular disease, breast cancer, gynecomastia, prostate cancer, acromegaly, and uterine cancer.
Applications
May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that KEOXIFENEcan be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e. G., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.Â
Â
Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.Â
Â
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.Â
Â
Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1Â Not indicated for reduction in the risk of noninvasive breast cancer.Â
Â
Â
Our advantage
a.Rich experience.We are a professional manufacturer in China for many years,our products have exported to Germany,Spain,UK,USA,Australia,Middle East and so many other countries,and we have got very good feedback from our customers,we had Established many long friendly relations of cooperation.
b.Great quality,purity and competitive price.Different country with different and suitable way of packing.Packing pictures will be sent to you as soon as possible after your payment.
c.Safe and fast delivery.We will send you with a safest and most suitable channel.
d.Good after-sales service.Our purpose is to hold a long friendly cooperation with our customers,so we will offer you best service from start to finish.
 Product Description
Alias:  KEOXIFENE; AKOS 9213 Purity: 99% MF: C28H28ClNO4S MW: 510.04 Appearance: Light yellow powder Related Substances: Pharmaceutical Grade Storage: Shading, confined preservation Manufacturer: YuanCheng Lead time: 1-2 days upon receipt of payment Usage: It is used in the prevention of osteoporosis in postmenopausal women. |
Description
KEOXIFENE is a second-generation Selective Estrogen Receptor Modulator (SERM) of the benzothiophene family. This drug is similar in effect to , exhibiting estrogen receptor antagonist (blocking) properties in some tissues while acting as an estrogen receptor agonist (activator) in others.
The main point of variation between these two agents is their tissue selectivity. While KEOXIFENE is a strong anti-estrogen in breast and uterine tissues, it appears to be estrogenic in bone. This allows it to protect bone density, mimicking the beneficial effects of endogenous estradiol. This is quite different from KEOXIFENE, which is anti-estrogenic in both breast and bone.
In a role that was novel for an anti-estrogen,KEOXIFENE was approved by the FDA for the prevention and treatment of osteoporosis in post-menopausal women. It is also being investigated for several other potential uses, including the treatment and prevention of cardiovascular disease, breast cancer, gynecomastia, prostate cancer, acromegaly, and uterine cancer.
Applications
May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that KEOXIFENEcan be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e. G., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.Â
Â
Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.Â
Â
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.Â
Â
Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1Â Not indicated for reduction in the risk of noninvasive breast cancer.Â
Â
Â
Our advantage
a.Rich experience.We are a professional manufacturer in China for many years,our products have exported to Germany,Spain,UK,USA,Australia,Middle East and so many other countries,and we have got very good feedback from our customers,we had Established many long friendly relations of cooperation.
b.Great quality,purity and competitive price.Different country with different and suitable way of packing.Packing pictures will be sent to you as soon as possible after your payment.
c.Safe and fast delivery.We will send you with a safest and most suitable channel.
d.Good after-sales service.Our purpose is to hold a long friendly cooperation with our customers,so we will offer you best service from start to finish.
Â
Electric Under Blanket is a specific type of Electric Blanket, usually used in European countries. It is placed below the bottom bed sheet, but cannot be above the bed sheet or over human body.
It normally has 3 to 4 heat settings as option. Consumers can choose their suitable temperature ranges.
Electric under blanket is normally used for sleeping, hence it normally shut off after 12 hours, or be turned off manually.
Below image as reference:
Electric Under Blanket
Electric Under Blankets, Heated Under Blanket, Electric Heated Blanket, Electric Blanket Safety
Ningbo Makeheat Electrical Appliance Co., Ltd , http://www.makeheat.net